- Tools for Investors
- Stock News
- Investing Ideas
- Econ & Policy
- Personal Finance
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 0.42%.
Isis Pharmaceuticals, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.03 in the quarter versus EPS of $-0.20 in the year-earlier quarter.
Revenue: Decreased 38.58% to $19.9 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Isis Pharmaceuticals, Inc. reported adjusted EPS loss of $0.03 per share. By that measure, the company beat the mean analyst estimate of $-0.23. It beat the average revenue estimate of $15.78 million.
Quoting Management: “2012 was a strong year for Isis. We begin 2013 in a significantly improved financial position with nearly $375 million in cash. Since the beginning of 2013, we have already received a $25 million milestone payment from Genzyme and a $7.5 million milestone payment from GSK. With the commercial launch of KYNAMRO and a maturing pipeline of drugs, we have many opportunities for significant near-term revenue from partnerships while we are also setting the stage for significant future revenue growth,” said Elizabeth L. Hougen, chief financial officer of Isis.
Key Stats (on next page)…
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
There's always a bull market in some sector! Find the best opportunities in commodities.